Tact.ai, an AI company focused on customer engagement for life sciences, has announced a successful new round of financing totaling $33 million. Investors for this round included McKesson Ventures, Lilly, Novartis (dRx Capital), Microsoft’s M12, and Salesforce Ventures. The company has now raised a total of $88 million.
Delivering individualized experiences for patients, especially over the past 18 months of the global COVID-19 pandemic, has been a big challenge for the life sciences industry. Tact helps organizations in the life sciences industry work more effectively with healthcare professionals and healthcare organizations—not only providing a platform for meetings but also delivering a personalized journey using relevant customer insights and scientific content.
“Our technology connects physicians and patients to the pharmaceutical ecosystem needed to help improve outcomes,” said Chuck Ganapathi, Founder and CEO of Tact.ai. “As these value-based conversations have shifted to be both in-person and virtual, life sciences organizations need a better way to deliver this hybrid experience. We’re very pleased to work with Novartis, Lilly and McKesson Ventures on making customer engagement more effective and human-friendly.”
Tact’s technology takes a holistic, outcome-focused approach to customer engagement in its many forms. This helps field teams be more productive and effective, as well as allowing customers to engage when and how they want to.
“As healthcare organizations prioritize interactions that improve patient outcomes, the opportunity to bring to market a next generation engagement platform for biopharma has emerged,” said Carrie Williams, Partner at McKesson Ventures, the investment fund of McKesson. “Tact.ai supports our thesis that commercial strategies for biopharma should account for both field force and prescriber needs, ensuring the right data is leveraged at the right time to enable the best decisions and support for patients.”
Read the full press release on PR Newswire.